liver transaminitis

Actionable Insights Powered by AI

BioAge Labs Discontinues Phase II Obesity Study Due to Safety Concerns, Stock Plummets

BioAge Labs, azelaprag, obesity treatment, Phase II study, safety concerns, liver transaminitis, stock crash